Abstract

Background. Recurrent ischemic stroke is associated with adverse neurological outcome in patients with atrial fibrillation. There is very scarce information regarding the neurological outcome of atrial fibrillation patients undergoing repeated systemic thrombolysis after early recurrent ischemic stroke. Clinical Case and Discussion. We describe a case of a 76-year-old woman with known paroxysmal atrial fibrillation who was admitted because of an acute right middle cerebral artery ischemic stroke and who underwent repeated systemic thrombolysis within 110 hours. The patient underwent systemic thrombolysis after the first ischemic stroke with almost complete neurological recovery. On the fourth day after treatment, an acute left middle cerebral artery ischemic stroke was diagnosed and she was treated with full-dose intravenous recombinant tissue plasminogen activator. A hemorrhagic transformation of the left middle cerebral artery infarction was noted on follow-up cranial computed tomographic scans. The patient did not recover from the second cerebrovascular event and died 25 days after admission. Conclusion. To the best of our knowledge, this is the second case reporting the adverse neurological outcome of a patient with diagnosis of atrial fibrillation undergoing repeated systemic thrombolysis after early recurrent ischemic stroke. Our report represents a contribution to the scarce available evidence suggesting that repeated systemic thrombolysis for recurrent ischemic stroke should be avoided.

Highlights

  • There is strong evidence that treatment of acute ischemic stroke with intravenous (IV) recombinant tissue plasminogen activator reduces long-term disability [1]

  • We report a case of repeated used of IV recombinant tissue plasminogen activator (rtPA) within 110 hours in a patient with early recurrent ischemic stroke associated to atrial fibrillation, and we discuss its pathophysiological, clinical, and prognostic implications

  • We report a case of repeated IV rtPA within less than 5 days in a patient with paroxysmal atrial fibrillation and recurrent acute ischemic stroke

Read more

Summary

Introduction

There is strong evidence that treatment of acute ischemic stroke with intravenous (IV) recombinant tissue plasminogen activator (rtPA) reduces long-term disability [1]. The repeated use of IV rtPA in the 3-month window may be associated to a higher risk of cerebral bleeding and to potential anaphylactic reactions [5].

Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call